Antitrust Antitrust

Covid-19 impact not deemed a legitimate factor for SAMR to lower antitrust fines

By Yonnex Li
  • 11 May 2020 01:26
  • 11 May 2020 01:26
China's antitrust regulator doesn't consider the economic hardship brought about by the Covid-19 epidemic as a legitimate mitigating factor to reduce fines for confirmed antitrust violations, MLex has learned.
The State Administration for Market Regulation, or SAMR, isn't empowered to factor in the epidemic because it is not among the

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Yonnex Li

Chief Correspondent, Greater China


Yonnex has an MA in Journalism from the Chinese University of Hong Kong, after obtaining a BA in Translation at the same university. At MLex, she writes extensively on antitrust developments in the Greater China region, including investigations, court cases and merger control of international transactions. Prior to joining MLex, she worked as a reporter at the English division of the Hong Kong Economic Journal, providing coverage and analysis on China's banking sector, asset management industry as well as currency and financial reforms.

Discover MLex

Stay on top of global regulatory developments

Latest News